IL161673A0 - Compositions and methods for therapy of chemotherapy-induced neuropathy - Google Patents

Compositions and methods for therapy of chemotherapy-induced neuropathy

Info

Publication number
IL161673A0
IL161673A0 IL16167304A IL16167304A IL161673A0 IL 161673 A0 IL161673 A0 IL 161673A0 IL 16167304 A IL16167304 A IL 16167304A IL 16167304 A IL16167304 A IL 16167304A IL 161673 A0 IL161673 A0 IL 161673A0
Authority
IL
Israel
Prior art keywords
chemotherapy
therapy
compositions
methods
induced neuropathy
Prior art date
Application number
IL16167304A
Other languages
English (en)
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Priority to IL16167304A priority Critical patent/IL161673A0/xx
Publication of IL161673A0 publication Critical patent/IL161673A0/xx
Priority to EP05737409.2A priority patent/EP1740200B1/fr
Priority to JP2007510235A priority patent/JP2007534746A/ja
Priority to DK05737409.2T priority patent/DK1740200T3/en
Priority to AU2005237324A priority patent/AU2005237324A1/en
Priority to PL05737409T priority patent/PL1740200T3/pl
Priority to EP16188978.7A priority patent/EP3124040B1/fr
Priority to US11/587,937 priority patent/US7951359B2/en
Priority to DK16188978.7T priority patent/DK3124040T3/da
Priority to CA002564390A priority patent/CA2564390A1/fr
Priority to PL16188978T priority patent/PL3124040T3/pl
Priority to PCT/IL2005/000444 priority patent/WO2005105135A1/fr
Priority to ES16188978T priority patent/ES2788131T3/es
Priority to ES05737409.2T priority patent/ES2657049T3/es
Priority to IL178636A priority patent/IL178636A0/en
Priority to NO20065471A priority patent/NO20065471L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL16167304A 2004-04-29 2004-04-29 Compositions and methods for therapy of chemotherapy-induced neuropathy IL161673A0 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
IL16167304A IL161673A0 (en) 2004-04-29 2004-04-29 Compositions and methods for therapy of chemotherapy-induced neuropathy
ES05737409.2T ES2657049T3 (es) 2004-04-29 2005-04-28 IL-6 para la terapia o prevención de neuropatías inducidas por quimioterapia
EP16188978.7A EP3124040B1 (fr) 2004-04-29 2005-04-28 Il-6 pour le traitement d'une neuropathie induite par une chimiotherapie
DK16188978.7T DK3124040T3 (da) 2004-04-29 2005-04-28 Il-6 til terapi af kemoterapi-induceret neuropati
DK05737409.2T DK1740200T3 (en) 2004-04-29 2005-04-28 IL-6 FOR THERAPY OR PREVENTION OF CHEMOTHERAPY-INDUCED NEUROPATHY
AU2005237324A AU2005237324A1 (en) 2004-04-29 2005-04-28 IL-6 for therapy or prevention of chemotherapy-induced neuropathy
PL05737409T PL1740200T3 (pl) 2004-04-29 2005-04-28 IL-6 do terapii lub zapobiegania neuropatii wywołanej chemioterapią
EP05737409.2A EP1740200B1 (fr) 2004-04-29 2005-04-28 Il-6 pour traitement ou prevention d'une neuropathie induite par une chimiotherapie
US11/587,937 US7951359B2 (en) 2004-04-29 2005-04-28 Compositions and methods for therapy or prevention of chemotherapy-induced neuropathy
JP2007510235A JP2007534746A (ja) 2004-04-29 2005-04-28 化学療法誘発性ニューロパシーの治療または予防のためのｉｌ−６
CA002564390A CA2564390A1 (fr) 2004-04-29 2005-04-28 Il-6 pour traitement ou prevention d'une neuropathie induite par une chimiotherapie
PL16188978T PL3124040T3 (pl) 2004-04-29 2005-04-28 IL-6 do terapii lub zapobiegania neuropatii wywołanej chemioterapią
PCT/IL2005/000444 WO2005105135A1 (fr) 2004-04-29 2005-04-28 Il-6 pour traitement ou prevention d'une neuropathie induite par une chimiotherapie
ES16188978T ES2788131T3 (es) 2004-04-29 2005-04-28 IL-6 para la terapia de neuropatías inducidas por quimioterapia
IL178636A IL178636A0 (en) 2004-04-29 2006-10-16 Compositions and methods for therapy of chemotherapy-induced neuropathy
NO20065471A NO20065471L (no) 2004-04-29 2006-11-28 Anvendelse av IL-6 for behandling eller forebygging av kjemoterapiindusert nevropati.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL16167304A IL161673A0 (en) 2004-04-29 2004-04-29 Compositions and methods for therapy of chemotherapy-induced neuropathy

Publications (1)

Publication Number Publication Date
IL161673A0 true IL161673A0 (en) 2004-09-27

Family

ID=34074041

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16167304A IL161673A0 (en) 2004-04-29 2004-04-29 Compositions and methods for therapy of chemotherapy-induced neuropathy
IL178636A IL178636A0 (en) 2004-04-29 2006-10-16 Compositions and methods for therapy of chemotherapy-induced neuropathy

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL178636A IL178636A0 (en) 2004-04-29 2006-10-16 Compositions and methods for therapy of chemotherapy-induced neuropathy

Country Status (11)

Country Link
US (1) US7951359B2 (fr)
EP (2) EP3124040B1 (fr)
JP (1) JP2007534746A (fr)
AU (1) AU2005237324A1 (fr)
CA (1) CA2564390A1 (fr)
DK (2) DK1740200T3 (fr)
ES (2) ES2788131T3 (fr)
IL (2) IL161673A0 (fr)
NO (1) NO20065471L (fr)
PL (2) PL1740200T3 (fr)
WO (1) WO2005105135A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112533642A (zh) * 2018-05-17 2021-03-19 赫利世弥斯株式会社 治疗与化疗诱发的周围神经病变相关的神经性疼痛

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL163856A0 (en) 2004-09-01 2005-12-18 Applied Research Systems Use of IL-6 in vascular complications
WO2009069133A2 (fr) 2007-11-28 2009-06-04 Hadasit Medical Research Services And Development Ltd. Procédés de traitement de lésion tissulaire induite par un rayonnement ou une chimiothérapie
US20130230580A1 (en) * 2010-09-14 2013-09-05 Paul S. Frenette Administration of SNS Neuroprotective Agents to Promote Hematopoietic Regeneration
EP3299032A1 (fr) 2016-09-23 2018-03-28 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Inhibiteurs de gpr132 destinés à être utilisés dans la prévention et/ou le traitement de la douleur neuropathique induite par chimiothérapie
WO2022256688A1 (fr) * 2021-06-04 2022-12-08 Sonnet BioTherapeutics, Inc. Méthodes de traitement de la fragilité liée à l'âge avec de l'interleukine-6

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5017691A (en) 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US4879111A (en) 1986-04-17 1989-11-07 Cetus Corporation Treatment of infections with lymphokines
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
DK0779362T4 (da) 1989-12-22 2012-07-30 Serono Lab DNA-konstruktioner til aktivering og modifikation af endogene geners ekspression
DE69230789T3 (de) 1991-01-18 2007-10-31 Amgen Inc., Thousand Oaks Methoden zur behandlung von durch den tumor nekrose faktor ausgelösten krankheiten
IT1247484B (it) 1991-03-22 1994-12-17 Ceinge Societa Consortile A R Metodo per la preparazione di interleuchina 6
WO1994003492A1 (fr) 1992-08-06 1994-02-17 The University Of Melbourne Variantes de l'interleukine-6 et leurs utilisations
IT1263022B (it) 1992-11-06 1996-07-23 Angeletti P Ist Richerche Bio Interleuchina-6 mutante con attivita' biologica migliorata rispetto all'interleuchina-6 selvatica.
IT1261787B (it) 1993-06-23 1996-06-03 Angeletti P Ist Richerche Bio Metodologia per la selezione di superagonisti, antagonisti e super- antagonisti di ormoni del cui complesso recettoriale fa parte gp 130.
US5635599A (en) 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
WO1997016202A1 (fr) * 1995-10-27 1997-05-09 Amrad Operations Pty. Ltd. Cytokines et leur utilisation dans le traitement et/ou la prophylaxie du cancer du sein
ES2312177T3 (es) * 1996-05-22 2009-02-16 Viventia Biotech Inc. Fragmentos de union a antigenos que detectan especificamente celulas cancerosas, nucleotidos que codifican los fragmentos y el uso de los mismos para la profilaxis y deteccion de canceres.
DE69830305T2 (de) * 1997-02-20 2006-02-02 Dime, David S., Toronto Ortsspezifische arzneimittel verabreichung
IT1291932B1 (it) * 1997-06-20 1999-01-21 Angeletti P Ist Richerche Bio Composizioni farmaceutiche antitumorali capaci anche di ridurre la farmacoresistenza in cellule tumorali, in particolare di carcinoma
IL122818A0 (en) 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
CA2379388C (fr) 1999-07-13 2012-05-29 George N. Cox, Iii Proteines de fusion d'immunoglobine
IL161310A0 (en) * 2001-10-11 2004-09-27 Applied Research Systems Use of a substance signaling through gp 130 in pns disorders
IL163856A0 (en) * 2004-09-01 2005-12-18 Applied Research Systems Use of IL-6 in vascular complications

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112533642A (zh) * 2018-05-17 2021-03-19 赫利世弥斯株式会社 治疗与化疗诱发的周围神经病变相关的神经性疼痛

Also Published As

Publication number Publication date
DK1740200T3 (en) 2018-01-08
PL1740200T3 (pl) 2018-04-30
US20080193409A1 (en) 2008-08-14
EP3124040A1 (fr) 2017-02-01
US7951359B2 (en) 2011-05-31
JP2007534746A (ja) 2007-11-29
WO2005105135A1 (fr) 2005-11-10
ES2657049T3 (es) 2018-03-01
CA2564390A1 (fr) 2005-11-10
NO20065471L (no) 2007-01-09
PL3124040T3 (pl) 2020-08-24
EP3124040B1 (fr) 2020-02-12
IL178636A0 (en) 2007-02-11
EP1740200B1 (fr) 2017-11-22
DK3124040T3 (da) 2020-04-20
AU2005237324A1 (en) 2005-11-10
EP1740200A1 (fr) 2007-01-10
ES2788131T3 (es) 2020-10-20
WO2005105135A8 (fr) 2006-12-07

Similar Documents

Publication Publication Date Title
EP1737482A4 (fr) Compositions et methodes de traitement de maladies
HK1110602A1 (en) Compositions and methods of using angiopoietin-like protein
IL184047A0 (en) Methods and compositions for treating amyloid-related diseases
EP1804832A4 (fr) Méthodes et compositions pour apport sans aiguille de macromolécules
EP1718331A4 (fr) Procedes et compositions pour le dosage d'allergenes
EP1933862A4 (fr) Procedes et compositions pour l'administration orale de proteines
IL189364A0 (en) Estrogen compositions and therapeutic methods of use thereof
EP1966246A4 (fr) Procédés et compositions servant à l'apport, sans aiguille, d'anticorps
EP1812031A4 (fr) Compositions et procedes de modification de biomolecules
IL191072A0 (en) Therapeutic compositions and methods
IL181896A0 (en) Methods and compositions for the treatment of hyperlipidemia
ZA200704768B (en) Stabilized ramipril compositions and methods of making
EP1763358A4 (fr) Compositions et methodes coupe-faim
IL179931A0 (en) Compositions and methods for treatment of cardiovascular disease
IL183709A0 (en) Compositions and methods for treating conditions of the nail unit
IL182943A0 (en) Ovr110 antibody compositions and methods of use
ZA200705297B (en) Methods and compositions for treating amyloid related diseases
EP1786265A4 (fr) Nouvelles compositions et procedes de traitement
IL186325A0 (en) Tizanidine compositions and methods of treatment using the compositions
EP1720563A4 (fr) Procedes et compositions de traitement de l'inflammation
HK1109576A1 (en) Aequorin-containing compositions and methods of using same
IL178636A0 (en) Compositions and methods for therapy of chemotherapy-induced neuropathy
GB0608398D0 (en) Pharmaceutical composition and method of using same
EP1773349A4 (fr) Methodes et compositions de traitement de la preeclampsie
IL178635A0 (en) Compositions and methods for therapy of chemotherapy-induced neuropathy